Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Wang, Fen-Juana | Ding, Yeb | Mao, Ying-Yingb | Jing, Fang-Yuanb | Zhang, Zhen-Yub | Jiang, Long-Fanga | Guo, Jian-Fenga | Sun, Xiang-Juea | Jin, Ming-Juanb | Chen, Kunb; *
Affiliations: [a] Center for Disease Control and Prevention of Xiaoshan, Hangzhou, Zhejiang, China | [b] Department of Epidemiology and Biostatistics, Zhejiang University School of Public Health, Hangzhou, Zhejiang, China
Correspondence: [*] Corresponding author: Kun Chen, Department of Epidemiology and Biostatistics, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou 310058, Zhejiang, China. Tel.: +86 571 88208190; Fax: +86 571 88208194; E-mail: ck@zju.edu.cn.
Abstract: Background:Accumulated studies have suggested that single nucleotide polymorphisms (SNPs) in microRNAs are associated with risk of colorectal cancer (CRC). Objective:We tested our hypothesis that rs11014002 in hsa-miR-603 may be associated with CRC risk with a crosstalk of life-related factors. Methods:We conducted a case-control study which included 102 CRC patients and 204 matched cancer-free controls in Xiaoshan County. Results:We observed that subjects with rs11014002 CT/TT genotype had an increased susceptibility for CRC (CT vs. CC: odds ratio (OR)=2.352, 95% confidence interval (CI): 1.142–4.840, P=0.020; CT+TT vs. CC: OR=2.031, 95% CI: 1.063–3.883, P=0.032). After stratification by lifestyle-related factors, similar results were found among nonsmokers (CT vs. CC: OR=2.753, 95% CI: 1.085–6.983, P=0.033; CT+TT vs. CC: OR=2.971, 95% CI: 1.188–7.435, P=0.020) and non-alcohol drinkers (CT+TT vs. CC: OR=3.279, 95% CI: 1.071–10.033, P=0.037). Conclusions:Our data suggest that hsa-miR-603 may be involved in colorectal tumorigenesis, and the genetic polymorphism in hsa-miR-603 is associated with CRC susceptibility.
Keywords: hsa-miR-603, polymorphism, colorectal cancer, susceptibility
DOI: 10.3233/CBM-140395
Journal: Cancer Biomarkers, vol. 14, no. 4, pp. 225-231, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl